Pancreatic Cancer Early Detection Program
https://www.facingourrisk.org/research-clinical-trials/study/20/pancreatic-cancer-early-detection
Clinicaltrials.gov identifier:
NCT02206360 (https://clinicaltrials.gov/show/NCT02206360)
Study Contact Information:
Jessica Maldonado, NP
Phone Number: 914-849-2530
Email: [email protected]
or
Joshua P Raff, MD
Phone Number: 914-849-7600
Email: [email protected]
About the Study
NOTE: This study is no longer recruiting patients.
This is a study looking at esophageal ultrasound as a screening for pancreatic cancer in high risk individuals. The study will enroll people with an inherited risk for cancer due to a BRCA2 or CDKN2A mutation with or without a family history of pancreatic cancer. The study will also enroll people with a first- or second-degree relative with pancreatic cancer with Lynch syndrome (MLH1, MSH2, PMS2, MSH6, EPCAM) or any of the following mutations BRCA1, P53, PALB2, APC, or ATM.
What the Study Entails
Enrolled subjects will undergo Endoscopic Ultrasound (EUS) alternating with Magnetic Resonance Imaging (MRI), every six to 12 months, for up to 5 years.
Study Lead Investigator
Principal Investigator: Joshua P Raff, MD
This Study is Open To:
NOTE: This study is no longer recruiting patients.
This Study is Not Open To:
NOTE: This study is no longer recruiting patients.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.